CytomX Therapeutics (NASDAQ: CTMX) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare CytomX Therapeutics to similar businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, risk and dividends.

Insider and Institutional Ownership

63.1% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 8.0% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares CytomX Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CytomX Therapeutics -42.44% -84.12% -11.12%
CytomX Therapeutics Competitors -5,713.56% -84.24% -35.59%

Earnings and Valuation

This table compares CytomX Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CytomX Therapeutics $15.04 million -$58.90 million -15.90
CytomX Therapeutics Competitors $290.27 million $35.99 million 53.21

CytomX Therapeutics’ rivals have higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and price targets for CytomX Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytomX Therapeutics 1 2 8 0 2.64
CytomX Therapeutics Competitors 954 3405 11909 239 2.69

CytomX Therapeutics presently has a consensus target price of $33.88, indicating a potential upside of 35.72%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.49%. Given CytomX Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics has less favorable growth aspects than its rivals.

Summary

CytomX Therapeutics rivals beat CytomX Therapeutics on 7 of the 12 factors compared.

About CytomX Therapeutics

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.